Science News coverage of

ESC Congress 2018
Aug. 25–29, 2018 | Munich, Germany

ESC/ACC/AHA/WHF Expert Consensus Document


Fourth Universal Definition of Myocardial Infarction (2018)
Kristian Thygesen, Joseph S. Alpert, Allan S. Jaffe, Bernard R. Chaitman, Jeroen J. Bax, David A. Morrow, Harvey D. White, et al.

Sunday's Hot Lines - Clinical Trials

Loading the player...

Ivor Benjamin, MD, president, American Heart Association, Mariell Jessup, MD, Chief Science & Medical Officer, and John Warner, MD, immediate past president review Sunday's breaking hot line science presented at the ESC Congress 2018 in Munich.

Attendees gather for the top science presented at ESC18 in Munich, Germany on August 26, 2018.

Attendees gather for the opening remarks at ESC Congress 2018 in Munich.

A Study of Rivaroxaban on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients

Alex Spyropoulos | New York, NY

A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors

Erin Bohula | Boston, MA

A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease

J. Michael Gaziano | Boston, MA

ASCEND (Aspirin Arm)
A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin and Omega-3 Fatty Acid Versus Placebo

Jane Armitage | Oxford, UK

Randomised comparison of bilateral versus single internal thoracic coronary artery bypass graft surgery: effects on mortality at ten years follow-up in the Arterial Revascularisation Trial

David Taggart | Oxford, UK

  • RESULTS: 10-year results did not show that bilateral internal thoracic coronary artery bypass graft was superior to single internal thoracic artery for coronary artery bypass graft surgery; mortality risk was similar.
  • ART on ISRCTN Registry (opens in new window)

Monday's Hot Lines Clinical Trials

Loading the player...

Ivor Benjamin, MD, president, American Heart Association, Bob Harrington, MD, president-elect, and John Warner, MD, immediate past president, review important findings in 4 clinical trials presented during ESC Congress 2018 in Munich.

Presenters at ESC Congress 18 during Hot Lines 3.

Monday presenters L-R: Claudio Rapezzi (ATTR-ACT); Jean-Francois Obadia (MITRA-FR); Patrick Serruys (GLOBAL LEADERS) during the Hot Lines 3 Session at ESC Congress 2018.

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

Claudio Rapezzi | Bologna, Italy

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Faiez Zannad | Vandoeuvre Les Nancy, France
A randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation and reduced left ventricular ejection fraction

Jean-Francois Obadia |Lyon-Bron Cedex, France

A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation

Patrick Serruys | Rotterdam, Netherlands

Monday's Articles in AHA Journals

Tuesday's Hot Lines - Clinical Trials

Loading the player...

Ivor Benjamin, MD, president, American Heart Association, John Warner, MD, immediate past president, and Bob Harrington, MD, president-elect discuss the top science presented during ESC Congress 2018 in Munich.

esc18_hotlines4-5_photos 800x450

From L-R: Nicholas Mills discusses the High-STEACS trial; Henning Bundgaard answers questions about POET; and Michael Mullen talks about results of AIMS on Tuesday in Munich.

Association of dietary quality and risk of cardiovascular disease and mortality in more than 218,000 people from over 50 countries

Andrew Mente | Hamilton, Canada

Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy

Sunao Kojima | Okayama, Japan

  • RESULTS: In elderly patients with hyperuricaemia, treatment with febuxostat reduced adverse events compared to patients not receiving the drug (primary endpoint: composite of cerebral, cardiovascular, and renal events, and any-cause death).
  • FREED trial on (opens in new window)

Drug-Coated Balloons vs. Drug- Eluting Stents in Small Vessel Interventions

Raban Jeger | Basel, Switzerland

Early versus deferred invasive examination and treatment of patients with Non-ST-segment elevation acute coronary syndrome

Thomas Engstrom | Copenhagen, Denmark

High-Sensitivity Troponin in the Evaluation of patients with Acute Coronary Syndrome

Nicholas Mills | Edinburgh, United Kingdom

Partial oral treatment of left-sided infectious endocarditis

Henning Bundgaard | Copenhagen, Denmark

Aortic Irbesartan Marfan Study

Michael Mullen | London, United Kingdom